| Bioactivity | Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria[1]. |
| Invitro | Barzolvolimab 以高特异性和亚纳摩尔亲和力结合 KIT 的细胞外结构域，并变构抑制干细胞因子 (SCF) 的激活[1]。 |
| Name | Barzolvolimab |
| CAS | 2438203-51-9 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Terhorst-Molawi D, et, al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2022 Nov 16. |